Fig. 2From: Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective studyProgression-free survival (PFS, A) and overall survival (OS, B) starting from first day of capecitabine monotherapyBack to article page